Skelaxin (metaxalone) is not considered addictive in the way opioids or benzodiazepines are. It carries no DEA scheduling, meaning the federal government does not classify it as a controlled substance with abuse potential. That said, it does affect the central nervous system and can produce sedation, which means misuse is still possible, especially when combined with other substances.
Why Skelaxin Has Lower Abuse Potential
Skelaxin works differently from muscle relaxants that do carry addiction risk. Its exact mechanism isn’t fully understood, but the FDA notes it likely works through general central nervous system depression rather than targeting the specific brain pathways involved in reward and craving. It doesn’t directly relax muscles either. Instead, it appears to reduce the perception of pain and tension through its sedative properties.
Compare this to carisoprodol (Soma), another muscle relaxant that is a Schedule IV controlled substance because it converts into a compound similar to a sedative drug once metabolized. Carisoprodol has documented rates of dependence, and users have reported addiction as a side effect. Skelaxin doesn’t share that pharmacological profile, which is a key reason it remains unscheduled.
Can You Still Develop a Problem With It?
The absence of a controlled substance designation doesn’t mean Skelaxin is risk-free. It produces drowsiness and dizziness, and some people find these effects pleasant or calming enough to take more than prescribed. Taking higher doses amplifies sedation and can create a pattern of misuse over time, even without the classic physiological dependence seen with opioids.
The bigger concern is what happens when Skelaxin is combined with other substances. The FDA warns that its sedative effects are additive with alcohol, benzodiazepines, opioids, and certain antidepressants. Deaths from deliberate or accidental overdose have occurred with metaxalone, particularly in combination with antidepressants or alcohol. Someone who routinely pairs Skelaxin with a drink or another sedating medication is at real risk, not just of dependence but of life-threatening respiratory depression.
Withdrawal and Discontinuation
There is no well-documented withdrawal syndrome specific to Skelaxin the way there is for drugs like benzodiazepines or opioids. Clinical literature does not describe a predictable set of symptoms that emerge when someone stops taking metaxalone after regular use. This is another marker that distinguishes it from truly addictive medications, where stopping abruptly triggers physical symptoms like sweating, tremors, or rebound anxiety.
That said, if you’ve been taking Skelaxin daily for weeks, you may notice your muscle pain or discomfort returns once you stop. This is not withdrawal in the pharmacological sense. It simply means the underlying condition is still present, since Skelaxin treats symptoms rather than healing the injury itself.
How Long You Should Take It
Skelaxin is approved for short-term relief of acute musculoskeletal pain, used alongside rest and physical therapy. The FDA label does not specify a maximum treatment duration, but the word “acute” is important. It’s designed for conditions that are expected to improve over days to weeks, not for chronic pain management.
The recommended dose for adults is 640 mg taken three to four times daily, with a maximum of 2,560 mg per day. Staying within this range and using it only for the duration your doctor recommends significantly reduces any risk of developing problematic use patterns. If you find yourself wanting to continue beyond the original treatment period, or increasing the dose on your own because the prescribed amount no longer feels effective, those are worth discussing with your prescriber.
What Overdose Looks Like
At prescribed doses, Skelaxin’s main side effects are drowsiness and dizziness. At higher doses, the picture changes. Overdose symptoms can include agitation, confusion, dilated pupils, and in serious cases, seizure-like activity, muscle rigidity, and dangerously high body temperature. One documented overdose case showed a blood concentration more than 30 times the normal peak level after a standard dose.
Skelaxin has also been linked to serotonin syndrome, a potentially dangerous condition where excess serotonin activity causes rapid heart rate, high body temperature, and muscle twitching. This risk increases when metaxalone is combined with antidepressants that also raise serotonin levels, particularly SSRIs. Fatalities from metaxalone overdose have almost always involved other drugs taken at the same time, reinforcing that the real danger lies in combinations rather than the medication alone.
How It Compares to Other Muscle Relaxants
Among commonly prescribed muscle relaxants, Skelaxin sits on the lower end of the abuse-risk spectrum. Carisoprodol (Soma) is the most frequently misused muscle relaxant and carries a Schedule IV classification. Cyclobenzaprine (Flexeril) is also unscheduled but has a more pronounced sedative effect that some people find habit-forming. Baclofen, used for spasticity, can produce physical dependence with long-term use and has a recognized withdrawal syndrome.
Skelaxin’s relatively mild sedation and lack of documented physical dependence make it one of the safer choices when a provider is concerned about a patient’s substance use history. It’s not entirely without risk, but for most people taking it as directed for a short period, addiction is not a realistic concern.